These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 25915869)

  • 41. Modulation of the renin-angiotensin-aldosterone system and cough.
    Lacourcière Y; Lefebvre J
    Can J Cardiol; 1995 Aug; 11 Suppl F():33F-39F. PubMed ID: 7664216
    [TBL] [Abstract][Full Text] [Related]  

  • 42. To study the efficacy of Losartan on urinary uric acid excretion in Thiazide induced hyperuricemic and hypertensive patients.
    Khan M; Khan RA; Islam F; Laghari J; Jamali SN
    Pak J Pharm Sci; 2011 Oct; 24(4):583-7. PubMed ID: 21959825
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Reduction in arterial stiffness with angiotensin II antagonism and converting enzyme inhibition. A comparative study among malay hypertensive subjects with a known genetic profile.
    Rehman A; Ismail SB; Naing L; Roshan TM; Rahman AR
    Am J Hypertens; 2007 Feb; 20(2):184-9. PubMed ID: 17261465
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of losartan versus candesartan on uric acid, renal function, and fibrinogen in patients with hypertension and hyperuricemia associated with diuretics.
    Rayner BL; Trinder YA; Baines D; Isaacs S; Opie LH
    Am J Hypertens; 2006 Feb; 19(2):208-13. PubMed ID: 16448895
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Which is a better treatment for hypertensive patients with diabetes: a combination of losartan and hydrochlorothiazide or a maximum dose of losartan?
    Nishimura H; Shintani M; Maeda K; Otoshi K; Fukuda M; Okuda J; Nishi S; Ohashi S; Kato S; Baba Y;
    Clin Exp Hypertens; 2013; 35(8):582-8. PubMed ID: 23496265
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Angioedema associated with angiotensin II receptor antagonists: challenging our knowledge of angioedema and its etiology.
    Chiu AG; Krowiak EJ; Deeb ZE
    Laryngoscope; 2001 Oct; 111(10):1729-31. PubMed ID: 11801934
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy and tolerability of nebivolol compared with other antihypertensive drugs: a meta-analysis.
    Van Bortel LM; Fici F; Mascagni F
    Am J Cardiovasc Drugs; 2008; 8(1):35-44. PubMed ID: 18303936
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial.
    Devereux RB; Dahlöf B; Gerdts E; Boman K; Nieminen MS; Papademetriou V; Rokkedal J; Harris KE; Edelman JM; Wachtell K
    Circulation; 2004 Sep; 110(11):1456-62. PubMed ID: 15326072
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effects of blood-pressure-lowering treatment in hypertension: 9. Discontinuations for adverse events attributed to different classes of antihypertensive drugs: meta-analyses of randomized trials.
    Thomopoulos C; Parati G; Zanchetti A
    J Hypertens; 2016 Oct; 34(10):1921-32. PubMed ID: 27454050
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of uric acid-lowering therapy on blood pressure: systematic review and meta-analysis.
    Qu LH; Jiang H; Chen JH
    Ann Med; 2017 Mar; 49(2):142-156. PubMed ID: 27689859
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Control of home blood pressure with an amlodipine- or losartan-based regimen and progression of carotid artery intima-media thickness in hypertensive patients: the HOSP substudy.
    Ohta Y; Kawano Y; Iwashima Y; Hayashi S; Yoshihara F; Matayoshi T; Takiuchi S; Kamide K; Nakamura S; Horio T
    Clin Exp Hypertens; 2013; 35(4):279-84. PubMed ID: 23530977
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Antihypertensive and renoprotective efficacy and safety of losartan. A long-term study in children with renal disorders.
    Ellis D; Moritz ML; Vats A; Janosky JE
    Am J Hypertens; 2004 Oct; 17(10):928-35. PubMed ID: 15485756
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Treatment of Hypertension: Favourable Effect of the Twice-Daily Compared to the Once-Daily (Evening) Administration of Perindopril and Losartan.
    Szauder I; Csajági E; Major Z; Pavlik G; Ujhelyi G
    Kidney Blood Press Res; 2015; 40(4):374-85. PubMed ID: 26160625
    [TBL] [Abstract][Full Text] [Related]  

  • 54. AT1 blockers and uric acid metabolism: are there relevant differences?
    Puig JG; Torres R; Ruilope LM
    J Hypertens Suppl; 2002 Jun; 20(5):S29-31. PubMed ID: 12184060
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Losartan versus atenolol-based antihypertensive treatment reduces cardiovascular events especially well in elderly patients: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
    Ruwald AC; Westergaard B; Sehestedt T; Kjeldsen SE; Lindholm LH; Wachtell K; Devereux RB; Ibsen H; Nieminen MS; Dahlöf B; Olsen MH
    J Hypertens; 2012 Jun; 30(6):1252-9. PubMed ID: 22499288
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
    Wachtell K; Hornestam B; Lehto M; Slotwiner DJ; Gerdts E; Olsen MH; Aurup P; Dahlöf B; Ibsen H; Julius S; Kjeldsen SE; Lindholm LH; Nieminen MS; Rokkedal J; Devereux RB
    J Am Coll Cardiol; 2005 Mar; 45(5):705-11. PubMed ID: 15734614
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group.
    Dahlöf B; Devereux R; de Faire U; Fyhrquist F; Hedner T; Ibsen H; Julius S; Kjeldsen S; Kristianson K; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H
    Am J Hypertens; 1997 Jul; 10(7 Pt 1):705-13. PubMed ID: 9234823
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Aliskiren vs. other antihypertensive drugs in the treatment of hypertension: a meta-analysis.
    Chen Y; Meng L; Shao H; Yu F
    Hypertens Res; 2013 Mar; 36(3):252-61. PubMed ID: 23154589
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The release of the substrate for xanthine oxidase in hypertensive patients was suppressed by angiotensin converting enzyme inhibitors and alpha1-blockers.
    Ohtahara A; Hisatome I; Yamamoto Y; Furuse M; Sonoyama K; Furuse Y; Hamada T; Katoh M; Watanabe M; Kinugawa T; Ogino K; Igawa O; Shimomura T; Murakami F; Yamamoto T; Shigemasa C
    J Hypertens; 2001 Mar; 19(3 Pt 2):575-82. PubMed ID: 11327632
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effects of combination treatment using anti-hyperuricaemic agents with fenofibrate and/or losartan on uric acid metabolism.
    Takahashi S; Moriwaki Y; Yamamoto T; Tsutsumi Z; Ka T; Fukuchi M
    Ann Rheum Dis; 2003 Jun; 62(6):572-5. PubMed ID: 12759298
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.